SCHEMBL5200993

SCHEMBL5200993

Cc1ccc(C2(CCOC3CCCCO3)CCCNC2)cc1C

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.39
SLC6A2 P23975 8/20 0.39
SLC6A3 Q01959 8/20 0.39
CYP2D6 P10635 3/20 0.36
KDM4C Q9H3R0 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TACR1 P25103 1/20 0.31
KCNH2 Q12809 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7077339 0.86 SLC6A4 (0.57) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL5203734 0.83 MEN1 (0.34) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL8452305 0.83 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL6957304 0.80 SLC6A2 (0.50) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL8290900 0.80 SLC6A4 (0.55) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL7751548 0.77 SLC6A4 (0.56) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL8291781 0.75 SLC6A3 (0.46) SLC6A4SLC6A2SLC6A3CYP2D6KDM4C
SCHEMBL7947168 0.75 SLC6A2 (0.48) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL6494323 0.74 CCR5 (0.37) NPC1MEN1KMT2AL3MBTL1TACR1
SCHEMBL9027925 0.74 SLC6A2 (0.67) SLC6A4SLC6A2SLC6A3CYP2D6TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1150970-B1 (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME SANOFI AVENTIS (FR) 2007-08-22 EP disclosed
US-6951940-B2 Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2005-10-04 US disclosed
US-20040072840-A1 Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2004-04-15 US disclosed
US-6642233-B1 Strong affinity and high selectivity for the human NK1 receptors of substance P. SANOFI-SYNTHELABO (FR) 2003-11-04 US disclosed
EP-1150970-A1 (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Sanofi-Aventis (FR) 2001-11-07 EP disclosed
WO-2000047572-A1 (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME SANOFI-SYNTHELABO (FR) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072840-A1 Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them TACR1, TACR2, KCNJ11 SLC6A4 1027/4885SLC6A2 1874/4885SLC6A3 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.